✦ LIBER ✦

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

✍ Scribed by Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, S.; Tibbitts, J.; Yi, J.-H.; Sliwkowski, M. X.; Jacobson, F.; Lutzker, S. G.; Burris, H. A.

Book ID: 125331579
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 153 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2009.26.2071

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2118 POSTER A phase I study of trastuzum

2118 POSTER A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer

✍ I.E. Krop; M. Beeram; S. Modi; N. Rabbee; S. Girish; J. Tibbitts; S.N. Holden; S 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Ado-trastuzumab emtansine (T-DM1): a nov

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

✍ Baron, J. M.; Boster, B. L.; Barnett, C. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 165 KB

5020 Pharmacokinetics (PK), safety, and

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

✍ H. Burris III; S. Vukelja; I. Krop; S. Modi; B. Klencke; S. Girish; M.X. Sliwkow 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase II Study of the Antibody Drug Conj

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy

✍ Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limenta 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB

A Phase II Study of Weekly Vinorelbine a

A Phase II Study of Weekly Vinorelbine and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

✍ Juan Lucas Bayo-Calero; José I. Mayordomo; Pedro Sánchez-Rovira; Ramón Pérez-Car 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 97 KB

A phase II study of afatinib (BIBW 2992)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

✍ Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Lisa A. Carey, Stephen Houston, Da 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 218 KB